News|Videos|February 10, 2023
Fixed-Duration Venetoclax in the Treatment of CLL
Seema Ali Bhat, MD, and Alexey Danilov, MD, PhD, discuss data updates on the use of fixed-duration venetoclax for the treatment of CLL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases
5